


Supplemental information

Efficient *in vivo* prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need

Dominique L. Brooks, Madelynn N. Whittaker, Ping Qu, Kiran Musunuru, Rebecca C. Ahrens-Nicklas, and Xiao Wang


Figure S1. Scheme for Generation of Humanized R408W Mice.

Wildtype Locus of the Murine Pah Gene (standard project)




blue boxes: murine exons

Wildtype Locus of the Human Pah Gene (standard project)



pink boxes: human exons

Gene Targeted Locus of the Pah Gene (standard project)



blue boxes: mouse exons; pink boxes: human exons; neo: neomycin cassette for selection in ES cells; loxP: recognition sequence for cre recombinase mediated neo removal

Gene Targeted Locus after cre mediated neo removal (included in project)




Figure S2. Phenylketonuria Phenotypes in Humanized R408W Mice.

(A) Homozygous R408W mouse with PKU as evidenced by hypopigmentation of the fur, on left, compared to heterozygous R408W non-PKU littermate, on right.

(B) Blood phenylalanine levels and weights of homozygous R408W PKU ($n = 8$ animals) and heterozygous R408W non-PKU ($n = 6$ animals) age-matched (6 weeks of age) colonymates. Lines = mean values. P values calculated with Mann-Whitney U test.






Figure S3. Scheme for Generation of Humanized 1066 Mice.

Wildtype Locus of the Murine Pah Gene (standard project)




blue boxes: exons

Wildtype Locus of the Human Pah Gene (standard project)



pink boxes: human exons

Gene Targeted Locus of the Pah Gene (standard project)



blue boxes: murine exons; pink boxes: human exons; neo: neomycin cassette for selection in ES cells; loxP: recognition sequence for cre recombinase mediated neo removal

Gene Targeted Locus after cre mediated neo removal (included in project)




Figure S4. Schematic of Dual-AAV Prime Editing System.

PE3 = prime editor 3; AAV = adeno-associated virus; SpPE2 max = *Streptococcus pyogenes* prime editor 2 max; ITR = inverted terminal repeat; Cbh promoter = chicken β-actin promoter with cytomegalovirus early enhancer element; SpCas9max = *Streptococcus pyogenes* Cas9 max; Npu-N = *Nostoc punctiforme* N-terminal split intein; Npu-C = *Nostoc punctiforme* C-terminal split intein; MMLV = Moloney murine leukemia virus; RT = reverse transcriptase; RNaseH = ribonuclease H; SV40 = simian virus 40; pA = polyadenylation signal; mU6 = mouse U6 promoter; sgRNA = single guide RNA; hU6 = human U6 promoter; epegRNA = engineered prime editing guide RNA. This figure was reproduced without changes from reference 16 [Davis, J.R., Banskota, S., Levy, J.M., Newby, G.A., Wang, X., Anzalone, A.V., Nelson, A.T., Chen, P.J., Hennes, A.D., An, M., et al. (2023). Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 10.1038/s41587-023-01758-z] in accordance with the terms of the Creative Commons Attribution 4.0 International License: <https://creativecommons.org/licenses/by/4.0/>.




Figure S5. Liver Function Tests in Treated PKU and Control Non-PKU Groups of Mice, Related to Figure 5.

(A) Blood aspartate aminotransferase (AST) levels and alanine aminotransferase (ALT) levels in homozygous PKU mice following treatment with 8×10^{11} vg AAV dose ($n = 4$ animals) or with 4×10^{11} vg AAV dose ($n = 3$ animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ($n = 3$ animals) age-matched (6 weeks of age) colonymates (1 blood sample per timepoint).

(B) AST levels and ALT levels in homozygous PKU mice following treatment with 8×10^{11} vg AAV dose ($n = 3$ animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ($n = 2$ animals) age-matched (10 weeks of age) colonymates (1 blood sample per timepoint).

(C) AST levels and ALT levels in compound heterozygous PKU mice following treatment with 1×10^{12} vg AAV dose ($n = 3$ animals), comparing levels at various timepoints up to 5 weeks following treatment to levels in untreated heterozygous non-PKU control ($n = 2$ animals) age-matched (6 weeks of age) colonymates (1 blood sample per timepoint).

Lines in graphs = mean values.




Table S1. pegRNAs.

P40	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC CUGAGAAAGGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P41	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC ACUGAGAAAGGGuCggGG<u>UAUUGUGGC</u>C CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P42	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC AACUGAGAAAGGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P43	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAACUGAGAAAGGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P44	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC CGAACUGAGAAAGGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P45	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC ACUGAGAAAGGuCggGG<u>UAUUGUGGC</u>C CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P46	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC AACUGAGAAAGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P47	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAACUGAGAAAGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P48	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC CGAACUGAGAAAGGuCggGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P49	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGGuCgcGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P50	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGGuCguGG<u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P51	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGGG<u>CggGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P52	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGG<u>CgcGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P53	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGGG<u>CguGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P54	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGG<u>CggGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P55	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGG<u>CgcGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA
P56	ACUUUGCUGCCACAAUACCUGUUGAGAGCUAUGCUGGAAACAGCAUAGCAAGUCAAUAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGC GAGAAGGG<u>CguGG</u><u>UAUUGUGGC</u>A CGGGUUCUACUAGUACGCCUAAACCAACUAGAA

Black bold = spacer sequence; red bold = RTT; blue bold = PBS; lower case indicates nucleotide substitution to be introduced by RTT.

Table S2. ngRNAs.

N1	UGAGAAGGGCCaAGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N2	UAGCGAACUGAGAAGGGCCaGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N3	UGAGAAGGGCCgAGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N4	UGAGAAGGGuCgAGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N5	UGAGAAGGGuCggGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N6	UGAGAAaGGuCgAGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N7	UGAGAAaGGuCggGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N8	ACUUUGCUGCCACAAUACCUGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N9	ACUUUGCUGCCACAAUACCcGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N10	ACUUUGCUGCCACAAUgCcGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N11	ACUUUGCUGCCACgAUgCcGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N12	UGAGAAGGGuCgcGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N13	UGAGAAGGGuCguGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N14	UGAGAAGGGgCggGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N15	UGAGAAGGGgCgcGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N16	UGAGAAGGGgCguGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N17	UGAGAAGGGaCggGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N18	UGAGAAGGGaCgcGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU
N19	UGAGAAGGGaCguGGUAUUGGUUUUAGAGCUAGAAAAGCAAGUAAAAAAGGCUAGUCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGUGCUUUU

Black bold = spacer sequence; lower case indicates position complementary to nucleotide substitution introduced by RTT.

Table S3. Sequence of C-terminal AAV Vector With pegRNA/ngRNA P56/N19.

CCACTCCCTCTCGCGCTCGCTCACTGAGGCCGGCGACCAAAGGTCGCCCAGCAGCCCCGGCTTGGCCGGCGGCCTCACTGAGCGAGCGAGCGCGAGCTTA
ATTAACCTAATTCACTGGCGCTGTTTACAACGTCGTGACTGGAAAACCTGGCGTACCAACTTAATCGCCTTGCAAGCACATCCCCCTTCGCCAGCTGGCGTAATA
CGGAAGAGGCCGACCGATGCCCTCCAACAGTGCAGCCTGAATGGGAATGGGACCGCCCTGTAGCGCCGCTAACGCGGGGGTGTGGGGTACGCGCA
CGCGTACCGCTACCTGCCAGGCCCTAGGCCGCTCTTCGCTTCTCCCTTCTCGCCACGTCGCCGCTTCCCGTCAAGCTAAATCGGGGCTCC
CTTAGGGTCCGATTAGTCGTTACGCCACCTGACCCAAAAACTGATTAGGGTGTAGTCAGCTAGTGGCCATGCCCTGATAGACGTTTTCGCCCTTGA
CGTTGGAGTCAGCTTAAATGGACTCTGTTCAACACTGGAAACACACTCAACCCATCTCGGTCTATTCTTGTATTAAAGGGATTTCGCCGATTCGCCCT
ATTGGTTAAAAAAATGAGCTGTTAAACAAACCTTAACGCGAATTAAACAAATTAACGCTACATTAGGGGACTTCCGGGAAATGTGCGCCGAAACCCCTAT
TTGTTTATTCTAAATACATCAAAATATGATCCGCTCATGAGACAATAACCCGATAAAATGCTCAATAATATTGAAAAGGAAGATGACTGATTCAACATTCG
TGCGCCCTATTCCCTTTGCGCATTTGCCCTCTGTTGCTACCCAGAAACGCTGGTGAAGTAAAGATGCTGAAGATCAGTGGGTGACAGTGGGTTA
CATCGAAGTGGATCTAACAGCGTAAGATCCTGGAGAGTTGCCCGAAGAACGTTTCAATGATGAGCACTTTAAAGTCTGATGTCATGTCAGTGGCGGTTATTATCCG
TATTGACGCCGGCAAGAGCAACTCGGTGGCGCATACACTATTCTCAAGATGACTGGGAGTACTCACAGCTACAGAGAACGATTCACGGATGGCATGACAGTAAG
AGAATTATGCGATGTCGCCATAACCATGAGTGAACACACTGCCCAACTTACTCTGACAAACGATCGGAGGACGAAGGAGTACACCGCTTTCGACAGGGGAA
TCATGTAACCTGCCCTGATGTTGGGAACGGGAGCTGAATGAGGCCATACCAACAGCAGGCGTACACACAGATGCCGTGAGCAATGCCAACATTTGCA
AACTGGGAACACTACTCTAGCTCCCGCAACAAATTAAAGACTGGATGGAGGCGATAAAAGTTCAGGACCCTCTCGCGCTGGCCCTTCCGGCTGGTTAT
TGCTGATAATCTGGAGGCCGGTGGGTGTCGGTATCATTCGCACTGGGCCAGATGGTAAGCCCTCCGTATGCTAGTTACACGACGGGAGTCAGGC
AACTATGGATGAAACGAAATAGACGATCCTGGATGAGTAGGGCTCACTGATTAAGCAGTGGTAACCTGGAGAACGAGTTACTCATATAACTTTAGATTAAAC
TCATTTTAATTAAAGGATCTAGGTGAAGATCTTGTGATAATCTGATGACAAATACCTTAACTGAGTGGCTTCTGTCAGGCTGAGCAGCCCTGAGAAAGAT
CAAAGGATCTTCTGGAGATCCTTTCTGCGCTTAATCTGCTTCAACAAACAAAAACCCACCGTACCCAGCGTGGTTTGTGCGGATCAAGGACTACCAACTCT
TTTCCGAGGTACTGGCTCAGCAGCGCAGATAACCAAAACTGTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACACTCTGAGCACCGCCTACATACCT
CGCTCTGTAATCTGTTACCACTGGCTGTCGGCATAGTCGTCTTACCGGGTTGACTCAAGACGATAGTTACCGGATAAGCGCAGCGCTGGCTGAAC
GGGGGGTCTGTCAGCACAGCCAGCTTGGAGCGACAGCCTACACCGAAGTGGACTACAGCTGAGCTATGAGAACGCCACGCTCCGAAGGGAGAACGGCGA
CAGGTATCCGGTAAGGGCTGGAGGAGCAGGAGCGCAGGGAGCTCCAGGGGAACAGCCTGGTATCTTATAGTCGTCGGGTTTCGCCACCTCTGACTTGA
CGCTGATTTTGTGATGTCCTGCTAGGGGGCGGAGCTATGGAAAACCCAGCAACCGCCCTTTCAGGTTCTGGCTTGTGCTGCGCTTGTGCTCATGTT
TCCTGCCATTCCCTGATTCTGTGATAACCGTATTACCGCTTGTAGTGAGCTGATACCGCTCGCCGAGCGACGCGCAGCAGTCACTGAGCGAGGAAGC
GGAAGAGGCCAAACGCCCTCCCGCGTTGCCGATTCAATGCACTGGCAGACAGGTTCCGACTGGAAAGCGGAGTCAGCGCACGCA
TAATGTAAGTTAGCTCACTATTAGGACCCAGCTTACACTTATGCTTCCGCTGATGTTGTGAGGATAACAAATTACACAGGAAACAGCTA
TGACCATGATTACGCCAGATTAAATAGGCTGCGCTGCTCACTGAGGCTTCTGCGGCTCTAGATCAGGTAACGGCTACCCATACACTACAGGTA
GAGCGAGCGCAGAGGGAGTGGCAACTCCATCACTAGGGCTTCTGCGGCTCTAGATCAGGTAACGGCTACATAACTACAGGTAATGGCCGCTGCTGACCG
CCCAACGACCCCGCCATTGACGTAATAGTAACGCCAATAGGGACTTCCATTGACGTAATGGGTGGAGTATTACGGTAAACTGCCACTTGGCAGTACATCAAGT
TATCATATGCCAAGTACGCCCTATTGACGTAATGACGTTAAATGGCCGCTTGCATTGCCCCAGTACATGACCTATGGACTTCTACTGGCAGTACATCTAC
GTATTAGTCATCGTATTACCATGGCAGGGTGAAGCCCACGTTCTGCTTCACTCTCCCATCTCCCCCTCCCCACCCCCAATTGTTATTATTATTAAATTAT
TTTGTGCGAGTGG
CGGCGCGCTCGGAAGATTCTTATGGCAGGGCGCCGGCGCCGGCGCTATGGAAAACCCAGCGGCAACCGCCCTTTCAGGTTCTGGCTTGTGCTGCGCC
CCGCTCCCGCGCCCTCGCCGCCGCCCGCTGACTGACCGCGTACTCCACAGGTGAGCGGG
GAGGTAGGGTTAAGGGATGGTGGGGTTAATGTTAATTACCTGGAGCACCTGCTGAAATCACTTTTCAAGGTTGGACCGGTGCCACCATGAAACGG
ACAGCGCAGGAAAGCAGTGGCTACCAAAGAAGCGAAAGTCAAGGATGTCACAGGAAATACCTGGGAAAGCAGACGTTACGACATCGCGCTGGAGCG
GATCACAACCTGCCCTGAGAATGGCTTATGCCAGCAATTGTTACCGAAATCGGCAAGGCTACCCGCAAGTACTCTCTACAGCAACATCATGAACTTTCAAG
ACCGAGATTACCCCTGCCAACGGCGAGTGGCAACTGGGAGATCTGAGACAGACAGGCAAAACGGGGAGATCTGGGATAAGGGGGGGGATTGGCACCCTG
AAAGTGTGAGCATGCCCAAGTGAATATGTAAGGAAAGACCGAGGTGAGCAGACAGCGGCTTCAAGAACAGGTCTATCTGCCAACAGGAAACAGGATAAG
AGAAAGAAGGACTGGGACCTAAGAAGTACGGCGCTCGACAGCCCCACCGTGGCTATTCTGCTGGTGGCAAAGTGGAAAGGGCAAGTCCAAGAACACTGAAG
AGTGTGAGGAGGCTCTGGGATCACCACATGGAGGAAAGCAGCTTCTGAGAGAACATCCCATGACTTCTGGAACCCAAGGGCTACAAAGAAGTAAAAAGGAC
ATCAAGCTGCCCTAAGTACTCTGCTGAGAACGGCTGGAGAACAGGCTGGAGAACGACATGCCGAGGAAACGACTGGCCCTGCCCTCAAATAT
GTGAACTCTGTTACTTGGCCGCCACTTGGGAGATCTGAGAACAGGCTGGGAGGATAATGACGAAACAGCTGGTGGAGACAGCAGACTCTGGAGAGATC
ATCGAGCAGATCAGCGAGTCTCCAGAGAGTGTGATCTGGCCACGCTAATGGACAAAGTCTGCTGCGCTTACACAAGCACCAGGATAAGGCCATCAGAGCAGGCC
GAGAATCATCCACCTGTTACCTGACCAATCTGGAGCCCCCTGCCCTCAAGTACTTGTGACACCACATGACCGGAAGAGGTACACCAGCACAAAGAGGTGCTG
GACGCCACCTGATCCACAGAGCATCACCGCCCTGACAGACACGGATCGACCTGCTCACTGGAGGTGACTCCGGCGGAAGCTCTGGTGGCAGCAAGCGGCC
GACGGCTCTGAATTGGAGGGCTTAAGAAGAAAAGGGTGGAGGGCTTAGCGGGAGGCTTAGCGGGAGACCCCTGACAGTGGAGGATAAGACGAGTATGACT
GAACAGGAGCTGGCTCTGGGACTTCCACCTGGGAGATCTGGGAGGAGACAGGAGGAGATGGGCTGGGGCTGGGGAGGAGGAGGAGGAGGAGGAG
AAGGCCCAGCTGCTGAGACCCCTGGGAAACTGGGATATAGGGCATGCCAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
GAGGGCAGAGATGGCTGACAGAGGGCAGGAAGGAGACAGTGGAGGGCAGGAAACACCCAAAGACAGCTGAGGGAGTCTGGGCAAAGCAGGAGTTGAG
CTGTTCATCCAGGATTCGAGAGATGGCAGCACCTCTGTAACCACTGACCAAGCCGGCACCTGTTAATGGGGCTCTGACAGCAGAGGCCTATCAGGAGATCAAG
CAGGGCTCTGACAGCACGCCACGGCTGGGAGATCTGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
GGGAG
GCCGCGAAGCTGACCATGGGACAGCCACTGGTACCTGGGACACCCAGTGGAGGGCCCTGGTGAAGCAGGAGCTCCAGTGGCTGCTTAACCCCGGATGACAC
TACCAAGCCCTGCTGCTGGACACCGATCGCGTCACTGGGCTTGTGCTGGCCCTGAATCCAGGCCACCCCTGCTGCCAGAGGAGGGCTGCGACACA
GACTCTGGGGCTCAAAAGAACCGCGACGGCAGCGAATTGAGTCTCCAAAGAAGAAGAGGAAAGTCAAGTGCACCTTATTGTAATTTGAGTGTCTATTGCTT
ATTGTAACCTTAAAGCTGCAATAACAAAGTAAACAAACATTGCTTATTTGTAAGGTTCAAGGCTGGGGAGATGGGAGGAGTGGGAGGAGTGGGAGGAG
AAAAGCACGACTGGGCCACTTTCAAGTGGGACTACGCTTATTGCTGTTAGCTGTTAGCTGTTAGCTGTTAGCTGTTAGCTGTTAGCTGTTAGCTGTT
TTCTCAAGGGGATATTATGCTCAACACACAAATTCTACAGTGGGAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
GAAATCCAAGCCTATCATGTAAGGAG
ACCGGGAGGGAGTGGCGAGCTCTCCACAGCTGTCGAGGGGGCCGGCGGGCTAGAGATGGGGCTGCGATCGGAATTCAAAAAAATCTAGTTGGGTT
AACCGCTAAGTGGAGAAGCCGTTGCGACCCGACTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
TGTTCCAGCATGCTCAACAGGAG
ATATGATACTCCATTAAAACATAATTAAAACCTGCAAAAGAAGATTAACTTACTCTACAGTCACTGAGTTCTGCTGTTTAAATAATTTGTAATTTGATCTCTTATA
ATTCTAATTATCTCTAACAGCCTGTATGCAAAATGAGGAATCATGGGAAATAGGCCCTTCCGCCCCGACCTTGCAGGACAGAACCCCTAGTGTG
GAGGTGG

Black bold = spacer sequence; red bold = RTT; blue bold = PBS; lower case indicates nucleotide substitution to be introduced by RTT.

Table S4. Assessment of Off-target Editing in R408W Homozygous HuH-7 Cells.

Genomic site	Protospacer/PAM sequence ^a	Amplicon (chromosome: position range) ^b	Treated sample 1 ^c	Treated sample 2	Treated sample 3	Control sample 1	Control sample 2	Control sample 3
PAH	ACTTTGCTGCCACAATACCTTGG	chr12:102840439-102840600	32.32	29.99	32.40			
OT1	ttTaTGTGCCA-AATACCTAGG	chr8:78462251-78462495	0.62	0.47	0.48	0.55	0.60	0.57
OT2	AagcgtgTGCCACAATACCTGGG	chr2:13589808+13589996	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT3	tCTaTGTGCCA-AATACCTGGG	chr4:169715128-169715285	0.95	0.61	0.66	0.59	0.75	0.89
OT4	AaTcTactGTCCA-AATACCTGGG	chr8:76707015-76707213	0.43	0.39	0.45	0.41	0.48	0.47
OT5	AggTTG-TaCCACAATACCTTGG	chr10:113490901-113491091	0.51	0.51	0.48	0.49	0.50	0.45
OT6	AgcTgGCTG-CACAATACCTTGG	chr13:56216964-56217162	0.55	0.43	0.47	0.50	0.44	0.47
OT7	tCTgcGgTGCCACAATACCTTGG	chr12:98762684+98762848	0.59	0.61	0.56	0.75	0.52	0.71
OT8	AgagTGCaGCCACAATACCTAGG	chr9:28448755+28448930	0.71	0.73	0.67	0.64	0.72	0.68
OT9	ACaaTactGTCCA-AATACCTAGG	chr6:450502043-45052196	0.71	0.64	0.78	1.53	0.78	1.39
OT10	AtTTATGaaGCCACAATACCTGGG	chr12:90309031+90309183	0.67	0.64	0.58	0.64	0.67	0.61
OT11	gtTTTGCTGCCACAAGACCTAGG	chr6:46216177-46216276	0.86	0.64	0.46	0.43	0.59	0.51
OT12	tgTTTGTtTGCCA-AATACCTTGG	chr7:136729999-136730159	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT13	ACTTcaCTGCCAatAATACCTGGG	chr2:195824652-195824785	0.95	0.78	1.11	0.89	0.81	0.84
OT14	ACTTTatATGaaCACAAATACCTGGG	chr9:117378303+117378482	0.48	0.54	0.39	0.54	0.61	0.47
OT15	tCTcTGCT-CCACAATACCTAGG	chr3:25365542+25365698	0.50	0.44	0.47	0.52	0.45	0.55
OT16	tCTgTGCTGCC-CAATACCTTGG	chr13:35884818+35884996	0.72	0.56	0.60	0.64	0.66	0.52
OT17	cCTcTtCT-CCACAATACCTAGG	chr21:27362728-27362863	0.80	0.64	0.62	0.65	0.79	0.66
OT18	gCTTTCTGCCAC-ATACCTGGG	chr1:84363379+84363574	0.55	0.56	0.57	0.47	0.57	0.47
OT19	Ag-aTGCTGCaACAATACCTAGG	chr18:3456273-3456460	0.80	0.54	0.61	0.62	0.54	0.55
OT20	AggTTCCtCCACAATACCTGGG	chr5:2961395+2961503	0.70	0.61	0.62	0.78	0.76	0.72
OT21	ACTTTGCaGCCACAtTACCTGGG	chr17:61009795+61009954	0.67	0.72	0.83	0.84	n.d.	1.22
OT22	A-TgTGA TcCCACAATACCTGGG	chr12:5650929-5651072	0.54	0.63	0.64	0.66	0.60	0.56
OT23	AtTcT-CTGCCAatAATACCTGGG	chr8:108304580-108304753	0.52	0.56	0.65	1.10	0.48	0.61
OT24	cCTTTGCTcCCtCAATACCTAGG	chr12:53011957-53012129	0.70	0.62	0.66	0.61	0.71	0.58
OT25	ACTTTGCaGCCACAtgACCTGGG	chr17:75547288+75547430	0.56	0.53	0.78	0.69	0.58	0.63
OT26	ACTTTGCTtCCAaATAATAgCTGGG	chr13:76387376-76387540	0.69	0.59	0.62	0.71	0.65	0.70
OT27	ACTTTGtTtCCACAATAgCTAGG	chr13:77055944-77056107	0.69	0.61	0.74	1.11	0.54	0.65
OT28	ACTTTGCTGCTtCCACAATCCTAGC	chr13:81974451+81974555	0.40	0.49	0.52	0.39	0.51	0.51
OT29	ACTTTGtTGCCACAcgACCTGGG	chr10:73226422+73226613	0.82	0.68	0.99	0.73	0.73	0.88
OT30	ACaTTGCTaCCACAATACCTAGT	chr11:1493022+1493184	0.72	0.71	0.64	0.65	0.69	0.64
OT31	AaTTTGCTGaCACAAgACCTTGG	chr11:10677426+10677544	0.50	0.59	0.35	0.46	0.47	0.53
OT32	AgTTTGCTtCCACAATACaTAGG	chr11:36513516+36513638	0.59	0.52	0.64	0.56	0.51	0.51
OT33	taTTTGCTGCCAgAAATACCTTGG	chr9:73068606-73068772	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT34	ACagTGCTGCCAaATAACCTGGG	chr15:78935858+78935995	0.62	0.64	0.77	0.61	0.52	0.63
OT35	ACTTgctCTGCCACcATACCTGGG	chrY:7231179+7231337	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT36	ACTTTGtaTGCCACAATAtCaTGG	chr7:24649482-24649678	0.64	0.63	0.73	0.59	0.74	0.71
OT37	ACTTTtCTGCCtCcATAACCTTGG	chr3:70299910+70300073	1.19	0.88	1.00	0.76	1.06	0.86
OT38	ACTTTGCT-CCACAATgCCTGGG	chr1:227324114-227324224	0.50	0.56	0.48	0.50	0.57	0.48
OT39	ACTTTGCTGCCACtGTAACCTGGG	chr4:20389722-20389855	0.62	0.52	0.53	0.51	1.02	0.48
OT40	ACTcTGCT-CCACAATAtCTGGG	chr4:101789193-101789357	0.58	0.64	0.56	0.69	0.64	0.66
OT41	tCTTGCT-CCACAATAtCTGGG	chr4:129408329+129408552	0.74	0.91	0.87	0.81	0.96	1.04
OT42	ACTTgGCTGCCACCA-ACCTGGG	chr18:23806155+23806259	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT43	ACTTTGCTG-CACcATAACCTGGC	chr1:70805762-70805954	0.57	0.55	0.53	0.61	0.53	0.50
OT44	ACTTTGCTGCCAC-ATACCAaTGT	chr1:216169709+216169886	0.51	0.50	0.51	0.78	0.47	0.65
OT45	AC-TTGCTGCCAaATAATgCCTTGG	chr5:52278218-52278389	0.66	0.96	0.67	0.59	0.68	0.60
OT46	ACTTTGCTGCCAaATAACCTGGG	chr5:59665136-59665275	0.45	0.50	0.47	1.43	0.51	0.51
OT47	ACTTTGCTGCC-CAAgACtTTGG	chr19:49082325+49082466	1.33	1.35	1.33	1.48	1.41	1.42
OT48	ACaTTGCTG-CAgAAATACCTTGG	chr12:50837080-50837226	0.79	0.77	0.67	0.72	0.76	0.75
OT49	AC-TgGCTGCCACcATAACCTGGG	chr12:79983294-79983445	1.22	0.85	0.83	0.88	0.86	0.74
OT50	ACTTT-CTGCCACAtgACCTGGG	chr12:126286065-126286233	0.65	0.80	0.76	0.72	0.82	0.79
OT51	ACTTTGCTGtAC-ATAACCTGGG	chr16:50829626+50829775	0.63	0.71	0.84	0.78	0.69	0.64
OT52	ACTTTGgTGCCAAcACATAACCTGGG	chr16:67891109-67891286	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT53	AccTTGCTG-CAgAAATACCTTGG	chr22:41811842+41811995	0.54	0.53	n.d.	0.48	0.69	0.46
OT54	ACTTCTGCTGgCACAAaACCTTGG	chr8:10512237+10512356	0.56	0.42	0.43	0.44	0.45	0.48
OT55	ACTTaGCTGCCAgAA-ACCTTGG	chr8:130760741+130760888	0.40	0.41	n.d.	0.45	0.43	0.56
OT56	AC-TTGCTGCCACAATACTTG	chr14:93610395+93610551	0.65	0.48	0.70	0.55	0.49	0.58
OT57	AaTTTGCTGCCACAATt-CTAGG	chr10:20442761-20442922	0.51	0.50	0.52	0.49	0.46	0.53
OT58	ACTTTGCT-CCACAtTACCCAGG	chr11:58176050-58176199	0.80	0.76	0.67	0.78	0.81	0.92
OT59	tCTTTGCTGCCA-AtTACCTGGG	chr15:29093086+29093232	0.65	0.58	0.59	0.55	0.63	0.62
OT60	ACTTTGCTG-CAAAATAACCTTGC	chr21:39088389+39088584	0.45	0.56	n.d.	0.49	0.46	0.61
OT61	ACcTTGCTGCCA-AACACCTTGG	chr2:160662807-160662949	0.72	0.60	0.51	0.66	0.52	0.52

OT62	ACaTTGCTGgCACAAT-CCTGGG	chr2:213255950+213256111	0.65	0.57	0.52	0.87	0.54	0.55
OT63	ACTTTGgTtCC-CAATAACCTTG	chr2:196036434-196036580	0.68	0.62	0.73	0.56	0.60	0.72
OT64	ACTcT-CTGCCACAATACTAGA	chrY:13436340-13436535	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT65	ACTTTtCT-CCACATTACCTTGG	chr6:39041870+39042064	0.56	0.75	0.50	0.59	0.82	0.73
OT66	ACcTTGCTG-CAgAATACCTTGG	chr6:27785457+27785633	0.58	0.62	0.59	n.d.	0.67	0.65
OT67	AgTTTGTGCCACAA-ACCAGG	chr6:9683015-9683167	0.47	0.57	0.67	0.60	0.57	n.d.
OT68	ACTTTGg-GCCAgAATACCTTAGG	chrX:13570761-13570950	0.51	0.49	1.25	0.64	0.56	0.55
OT69	ACcTTGtTGCCA-AATACCTTGG	chrX:48090226-48090407	0.62	0.64	0.71	0.81	0.65	0.75
OT70	AtTTTGTGCCACAA-ACCAGG	chrX:106057761-106057923	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT71	ACTgTGCTGCaACAA-ACCTTGG	chrX:143235479-143235619	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT72	ACTTTGCT-CCACAAATgCCTGGT	chr7:155177942+155178085	0.60	0.56	0.62	0.58	0.57	0.55
OT73	AC-TTGA TGCCACAATACTGGG	chr3:72392649-72392845	0.44	0.56	0.38	0.45	0.48	0.43
OT74	ACTcTGCTGCCACAGT-CCTAGG	chr3:133006042+133006198	0.48	0.40	0.44	0.51	0.31	n.d.
OT75	ACTcTGaTGCCACAGATACTGGG	chr3:171524879+171525051	0.58	0.79	0.51	0.60	0.45	0.72
OT76	tCTTTGCT-CCACAAATATCTGGG	chr3:169677452-169677627	0.48	0.54	0.60	0.58	0.59	0.51
OT77	tCTTTGCTGCCAC--TACCTTGG	chr1:184534886-184535019	0.91	0.86	0.99	0.99	0.69	0.80
OT78	ACTTTGCTGC--CAATACTTTGG	chr15:40233992+40234119	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
OT79	ACcTTGCTGCCAC--TACCTGGG	chr2:98883002-98883164	0.72	0.59	0.62	0.74	0.65	0.63

^aThe PAH on-target sequence and top ONE-seq-nominated and in-silico-nominated candidate off-target sequences with mismatched positions and bulges indicated by lower case letters and dashes.

^bCoordinates in the GRCh38/hg38 assembly of the human genome; “+” and “-” indicate forward or reverse orientation of protospacer/PAM sequence.

^cn.d. = PCR was unsuccessful for the genomic site.